- By Tyler Landrith, PhD
- Posted March 5, 2020
Study Published in Nature Partner Journal Precision Oncology Confirms Clinical Utility of Simultaneous RNA and DNA Genetic Testing
DNA-based multigene panel testing (MGPT) is a commonly used approach for the detection of patients with or at-risk for inherited cancers. Despite years of advancement in genetic testing, patients may still receive uncertain results or receive a negative result despite having a personal or family history suggestive of hereditary cancer. RNA …
- By Holly LaDuca, MS, CGC
- Posted January 7, 2020
Study Demonstrates that RNA Genetic Testing Reduces Inconclusive Results Providing More Clarity to Patients and Healthcare Providers
Genetic testing plays a critical role in the delivery of personalized medicine. Take, for instance, hereditary cancer, where genetic testing can help inform treatment and other management decisions for both individuals with an active cancer diagnosis and those at an increased risk for cancer. For the latter, genetic testing helps minimize their …
- By Marcy Richardson, PhD - Variant Assessment Scientist
- Posted September 10, 2019
3 Ways RNA Analysis will Change the Future of Genetic Testing
When it comes to medical questions, sometimes “unknown” is the worst answer you can receive. Uncertainty prevents a family from developing an action plan to combat bad news, or from achieving peace of mind when receiving good news. Yet for many patients who undergo genetic testing due to a suspected hereditary cancer syndrome, they are left …
- By Jessica Profato
- Posted May 7, 2019
RNA Genetic Testing Brings Clarity to Lynch Syndrome Patients
MSH2 is one of five genes associated with Lynch syndrome, a condition that leaves patients with a significantly increased risk for colorectal and certain other cancers. Using genetic testing to identify patients with Lynch syndrome is important because they can be recommended increased cancer screenings for early detection and prevention. MSH2, …
